Trials / Completed
CompletedNCT03801837
Effect of Macadamia Nut on Cardiometabolic Risk Factors
Macadamia Nut Effects on Adiposity and Cardiometabolic Risk Factors
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Loma Linda University · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This research study will test the effects of macadamia nuts on adiposity, and traditional and emergent risk factors of cardiometabolic disease in adult men and women
Detailed description
Purpose of this study is to investigate the effects of Macadamia nuts on body weight, adiposity, , oxidative stress, glucose, insulin an lipid levels. it will a randomized cross over study that will include two study diets (Macadamia nut diet and control diet) with a wash out period of 4 weeks in between. 40 subjects will be selected and randomized into either of the two phases. During the Macadamia nut diet phase subjects will be provided the appropriate portion of Macadamia nuts (15% of daily calories or 30-45 grams based on kcal requirement of the individual, instructions will be provided on how to incorporate nuts into the diet. this phase will last for 8 weeks. During the control diet phase, subjects will continue with their normal diet and abstain from eating nuts. subjects will be tested for various outcomes at baseline and twice at the end of each phase. The intervention will last for 5 months in total.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Macadamia Nut | Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\] |
| DIETARY_SUPPLEMENT | Control Diet | Participants will continue with their Habitual Diet during this part of the intervention |
Timeline
- Start date
- 2019-06-24
- Primary completion
- 2019-11-25
- Completion
- 2019-11-25
- First posted
- 2019-01-14
- Last updated
- 2023-03-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03801837. Inclusion in this directory is not an endorsement.